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Our work reports for the first time the repositioning of gefitinib and afatinib, two 
anticancer EMA/FDA approved drugs, to treat head and neck squamous cell carcinoma 
(HNSCC) in Fanconi anemia, a rare disease whose patients currently have surgical 
resection as their only therapeutic option. We screened existing drugs for antitumor 
activity and identified both candidates using a combination of cell-based and in vivo 
mouse models. Our team recently obtained orphan drug designation (ODD) by EMA for 
gefitinib (EU/3/18/2075) and afatinib (EU/3/18/2110) (FDA ODD pending), with the 
midterm goal to organize a multicenter, international clinical trial to prove that 
gefitinib/afatinib improve the follow up of these patients when diagnosed with HNSCC. 
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Purpose: Fanconi anemia (FA) rare disease is characterized by bone marrow failure 
and a high predisposition to solid tumors, especially head and neck squamous cell 
carcinoma (HNSCC). FA patients with HNSCC are not eligible for conventional 
therapies due to high toxicity in healthy cells, predominantly hematotoxicity, and the 
only treatment currently available is surgical resection. In this work we searched and 
validated two already approved drugs as new potential therapies for HNSCC in FA 
patients. 
Experimental design: We conducted a high-content screening of 3,802 drugs in a 
FANCA-deficient tumor cell line to identify non-genotoxic drugs with cytotoxic/cytostatic 
activity. The best candidates were further studied in vitro and in vivo for efficacy and 
safety. 
Results: Several FDA/EMA-approved anticancer drugs showed cancer-specific 
lethality or cell growth inhibition in FA HNSCC cell lines. The two best candidates 
gefitinib and afatinib, EGFR inhibitors approved for non-small-cell lung cancer 
(NSCLC), displayed non-tumor/tumor IC50 ratios of ~400 and ~100 times, respectively. 
Neither gefitinib nor afatinib activated the FA signaling pathway or induced 
chromosomal fragility in FA cell lines. Importantly, both drugs inhibited tumor growth in 
xenograft experiments in immunodeficient mice using two FA patient-derived HNSCCs. 
Finally, in vivo toxicity studies in Fanca-deficient mice showed that administration of 
gefitinib or afatinib was well-tolerated, displayed manageable side-effects, no toxicity to 
bone marrow progenitors and did not alter any hematological parameters.  
Conclusions: Our data present a complete preclinical analysis and promising 
therapeutic line of the first FDA/EMA approved anticancer drugs exerting cancer 
specific toxicity for HNSCC in FA patients.  
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Fanconi anemia is a rare genetic disease, caused by mutations in at least 22 genes, 
which encode for proteins involved in interstrand-crosslink DNA repair. FA patients 
suffer from bone marrow failure, congenital abnormalities and a high incidence of 
malignancies, such as solid tumors and leukemias (1,2). The management of the 
hematological phenotype has been remarkably improved over the last 20 years, thanks 
to optimized hematological stem cell transplantation protocols, leading to an important 
increase in FA patient survival, from less than 20 years of age in the 1990s to more 
than 30 years observed today (3,4). The prevention and treatment of solid 
malignancies are expected to further impact the survival and quality of life of these 
patients (5). While there are some studies on chemoprevention, with chronic treatment 
proposals such as quercetin or metformin (6,7), few therapeutic options are available 
beyond surgical resection once solid malignancies appear (8,9). The most frequent 
solid tumors, accounting for up to 50 %, are HNSCC, with an incidence 700-fold higher 
than in the general population. Patients can tolerate complex surgeries for oral tumor 
removal, but usually receive mild chemotherapy, radiotherapy, or a combination, that 
yields moderate to high toxicities, with low survival rates of around 30 months (4,8,9). 
In this study, we searched for anticancer drugs approved by the American Food and 
Drug Administration (FDA) and/or European Medicines Agency (EMA) that could be 
repositioned to treat HNSCC in FA patients thanks to the induction of cancer specific 
lethality and identified several approved drugs (10,11). The best drugs from this 
screening were thoroughly studied in vitro and in vivo, obtaining complete preclinical 
data and a solid basis to present the first, non-toxic and potentially therapeutic option 
for FA patients with HNSCC. 
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MATERIALS AND METHODS 
Cell lines and Reagents 
Wild type (PN) and FANCA-deficient (FA551) primary fibroblasts, WT (VU040-T), FA-
derived 1131 (VU1131-T2.8, FANCC-/-), 1604 (VU1604-T, FANCL-/-) and 1365 
(VU1365-T, FANCA-/-) and SCC25 and Detroit 562 HNSCC cell lines, were grown in 
DMEM (Biowest) supplemented with 10 % heat inactivated FBS and plasmocin (ant-
mpt, Invivogen). WT and FANCA-deficient lymphoblastoid cell lines were grown in 
DMEM supplemented with 20 % heat inactivated FBS, sodium pyruvate (Gibco), non-
essential amino acids (Gibco), beta-mercaptoethanol (Gibco) and plasmocin. HNSCCs 
were kindly provided by Dr Josephine Dorsman, from VU University Medical Center, in 
Amsterdam (Netherlands). Non-FA HNSCC cell lines were from ATCC. Diepoxibutane 
(DEB, 202533), hydroxyurea (HU, H8627) and Mitomycin C (MMC, M0503) were 
purchased from Sigma. Drugs for in vitro studies, gefitinib (HY-508945), AEE788 
(14816), afatinib (11492), AZD9291 (16237), ceritinib (19374), CO-1686 (16244) and 
vandetanib (14706) were from Cayman Chemical and Cetuximab/Erbitux® was from 
Merck. For in vivo studies, drugs gefitinib/Iressa® (AstraZeneca) and afatinib/Giotrif® 
(Boehringer Ingelheim) were used, and vehicles Tween-80 (P4780), methylcellulose 
4,000cP (M0512) and alpha-lactose (L3625) were from Sigma. 
Screening validation 
A total of 3,800 drugs high-content screening was previously described (Montanuy et 
al, submitted). For non-genotoxic candidate validation, FA primary fibroblasts and FA 
HNSCC cell lines were seeded in 384 well plates, treated with candidate drugs at 1 
micromolar concentration per duplicate and cultured for 7 days. Cells were then fixed, 
Hoechst stained and nuclei images taken with ImageXpress confocal microscope 
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(Molecular Devices, representative images in Supplementary Figure 1A). Nuclei in 
each well were counted with CellProfiler software.  
Survival assays 
Seeded cells in 96 well plates were exposed to 9 different concentrations of MMC or 
antitumor drugs and cultured for 3 or 7 days. Cell growth and survival was measured 
with sulforhodamine B (SRB) staining assay (12). IC50 was determined by calculating 
logarithmic normalized trend lines with GraphPad. To identify best antitumor 
candidates, we calculated a ratio from IC50 of non-tumor cell lines (primary fibroblasts) 
vs averaged IC50 of the averaged three FA HNSCC cell lines. 
Western blot 
Western blot was performed as described earlier (13). FANCD2 (Ab2187), total ERK1 
(Ab32537), phosphorylated ERK1/2 (pT202/pY204 for ERK1, pT185/pY187 for ERK2; 
Ab50011), total AKT (Ab32505) and Vinculin (Ab18058) antibodies were from Abcam. 
Ser473 phosphorylated AKT (9271T), total EGFR (4267T) and Tyr1068 phosphorylated 
EGFR (3777T) antibodies were from Cell Signaling. 
Chromosome fragility and cell cycle analysis 
Chromosome fragility in cell lines was measured for 48 hours with flow cytometric 
micronucleus (FCM) assay, as described earlier (14–16). Micronuclei (MN) frequency 
was expressed as the number of MN per thousand nuclei. Percentage of cells arrested 
in G2/M phase of the cell cycle was obtained from nuclei plots. For in vivo chromosome 
fragility in mice, genotoxicity was measured in erythrocytes and reticulocytes from 
peripheral blood of wild type and Fanca-deficient mice as previously described (17). 
Briefly, peripheral blood was drawn from mice tail (~100 μL), collected into EDTA 
containing tubes, fixed in methanol and stored at -80 ºC. Samples were then incubated 
with anti-CD71-FITC antibody to select reticulocytes from erythrocytes, and stained 
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with propidium iodide to detect micronuclei. FACS analysis was performed in a 
FACSCanto cytometer (Becton Dickinson). 
 
Gene sequencing of HNSCC cell lines 
To analyze mutations in cancer related genes (including EGFR) in HNSCC cell lines, 
we used TruSight Tumor 15 (Illumina), a next-generation sequencing panel designed to 
identify sequencing variants in 15 genes commonly mutated in solid tumors and 
associated with marketed therapeutics (AKT1, BRAF, EGFR, ERBB2, FOXL2, GNA11, 
GNAQ, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, RET and TP53).  
In vivo xenograft experiments 
NOD-SCID mice (both sexes, age 6-9 week old, Charles River) were injected 
subcutaneously in the right flank with a mixture 1:1 of 1x106 FA-HNSCC cells-matrigel 
(Corning). Animals were monitored twice a week (body weight and tumor volume) until 
tumors were ≈150 mm3. Animals were then randomized into 4 experimental groups 
(n=8 animals/group): 1) Vehicle (0.5 % Tween-80); 2) Gefitinib; 3) Vehicle (0.5 % 
methylcellulose); 4) Afatinib. Treatments were administered 5 days a week orally 
(gavage): gefitinib/Iressa® 150 mg/kg and afatinib/Giotrif® 20 mg/kg (18–21). Vehicles 
were further supplemented with lactose at 98 mg/kg and 117 mg/kg respectively, to 
pair excipients in the medicinal products. Animals were monitored three times a week 
(body weight and tumor volume) until tumors were ≈1,000 mm3. Tumor volume was 
determined by using the formula: (length × width2) × (pi/6). At end-point animals were 
euthanized, and tumors were surgically removed. Tumor specimens were formalin-
fixed and paraffin-embedded for routine histological analysis. Animal experiments were 
performed under protocols approved by the Vall d’Hebron Ethical Committee for Animal 
Experimentation and the appropriate governmental agency and carried out in 
accordance with the approved guidelines. 
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Tumor samples excised from mouse xenograft experiments were fixed in 4 % formalin. 
For IHC, NovoLink polymer detection system (Novocastra Laboratories) was used. 
Anti-phopho-ERK1 (pT202/pY204)/ phospho-ERK2 (pT185/pY187) immunostaining 
(1:200 dilution) was carried out after heat-induced antigen retrieval (4 min, pressure 
cooker) with 10 mM citrate buffer pH 6.0, and then counterstained with hematoxylin 
and mounted. 
In vivo toxicity experiments in Fanca-deficient mice 
Fanca-deficient mice were previously described (22). Wild type and Fanca-deficient 
mice (female, age ranging from 8 to 20 weeks) were weight randomized into 4 
experimental groups and started to receive treatment (n=6 animals/group): 1) Vehicle 
(Tween-80); 2) Gefitinib; 3) Vehicle (Methylcellulose); 4) Afatinib. Treatments were 
administered 5 days a week orally (gavage): gefitinib 150 mg/kg and afatinib 20 mg/kg, 
for two weeks. Animals were monitored three times a week (body weight), and tail bled 
at 0 (pretreatment) and 14 days (end-point) of treatment. At end-point, animals were 
euthanized and bone marrow from femurs extracted for further analysis. 
FACS analysis of hematopoietic cell populations 
For counting LSK+ cells from bone marrow, we selected Lin- (all FITC-labeled: TER-
119, from eBiosciences; B220, RA3-6B2 from Biolegend; CD3, 145-2C11 from BD 
Biosciences; CD11b/Mac1, M1/70 from Biolegend; GR1, RB6-8C5 from Biolegend), C-
Kit+ (C-Kit PE/Cy7, 2B8 from Biolegend) and Sca-1+ (Sca-1 PE, E13-161-7 from BD 
Biosciences) cells. For peripheral blood cells, the following antibodies were used: 
B220-FITC (RA3-6B2), GR1-PE (RB6-8C5), CD4-BV711 (RM4-5) and CD11b/MAC1-
AF647 (M1/70) were from Biolegend; CD3-PEvio770 (145-2C11) was from Milteny; 
CD8-PECy5 (53-6-7) was from BD Biosciences. T lymphocyte (CD3+), B lymphocytes 
(B220+) and myeloid cells (non-T, non-B cells) were gated in the region of live 
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leucocytes from FSC-A, SSC-A and DAPI parameters. CD4+ and CD8+ cells were 
quantified from CD3+ cells. Myeloid cell subpopulations GR1+MAC1+ (mainly 
neutrophils and other granulocytes) and GR1-MAC1+ (mainly monocytes, macrophages 
and dendritic cells)(23) were quantified from CD3-B220- cells.  
Blood hematology and bone marrow colony formation unit assays 
Peripheral blood was drawn from mice tail (~100 μL), collected into EDTA containing 
tubes (Sarstedt) and counts were determined using an Abacus Junior Vet hematology 
analyzer (Diatron). Number of colony forming unit-granulocyte/macrophage (CFU-GM) 
progenitors present in total bone marrow was performed as described earlier (22). 
Statistics 
All experiments were performed using triplicate repeats unless otherwise stated, and 
data present means ± SEM. Statistical significance was tested using Student’s T test, 









EGFR inhibitors selectively inhibit the growth of FA HNSCC cell lines 
From a previous screening in FANCA-deficient tumor cells (Montanuy et al., submitted) 
we sought to find non-genotoxic drugs that induce cancer-specific cytotoxicity. We 
Research. 
on February 6, 2020. © 2020 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 31, 2020; DOI: 10.1158/1078-0432.CCR-19-1625 
11 
 
used primary fibroblasts from FA donors as non-tumor cells and three different FA 
patient-derived HNSCC cell lines: 1131 (FANCC deficient), 1604 (FANCL deficient), 
and 1365 (FANCA deficient) (24). From 150 selected candidates, validation analysis at 
a concentration of 1 micromolar identified seven anticancer drugs: ceritinib, an 
anaplastic lymphoma kinase (ALK) inhibitor, used to treat NSCLC (25); CO1686 
(rociletinib), a second-generation EGFR inhibitor; AZD9291 (osimertinib), a third-
generation EGFR inhibitor approved for patients with EGFR T790M mutation-positive 
metastatic NSCLC (26); vandetanib, a multikinase inhibitor including EGFR, vascular 
endothelial growth factor 2 (VEGFR2) and RET, approved for thyroid cancer (27); 
AEE788, also a dual inhibitor of EGFR/ERBB2 and VEGFR2; gefitinib, a first-
generation inhibitor of EGFR, also approved to treat NSCLC (28); and afatinib, a 
second-generation EGFR inhibitor, also used to treat NSCLC (Figure 1A, 1B, and S1A-
F) (29). Interestingly, other EGFR and VEGFR inhibitors, such as erlotinib and 
vatalanib, did not have or had a low non-tumor/tumor ratio in the cell lines tested, 
probably due to different cell line sensitivities that these drugs may exert (data not 
shown). In this sense, cetuximab treatment, a highly specific EGFR-targeting antibody 
used to treat HNSCC in the general population, among other malignancies (30) 
inhibited growth in all FA HNSCC cell lines, while having no effect in primary 
fibroblasts, showing specific dependency of EGFR pathway for FA HNSCC growth 
(Figure S1G).  Subsequent cytotoxicity assays with doses ranging from low nanomolar 
to micromolar concentrations showed, as expected, that the DNA crosslink-inducer 
mytomycin C (MMC) was highly toxic both in FA HNSCC cell lines as well as primary 
cells, at less than 1 nM (Figure 1C). In sharp contrast, gefitinib and afatinib were the 
drugs that best inhibited growth in all three HNSCC cell lines derived from FA patients, 
while having a much lower effect in primary FA fibroblasts (Figure 1D-E). Gefitinib 
produced a sensitivity ratio of non-tumor versus tumor cell lines of 386 times, and 
afatinib 112 times, exerting its antitumor effect at a low nanomolar concentration (the 
IC50 for HNSCCs averaged 25.3 nM for gefitinib and 10.8 nM for afatinib; see Figure 
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1F). Other drugs with good antitumor profile were AEE788 (with an average IC50 of 
28.4 nM), AZD9291 (IC50 64.2 nM) and vandetanib (IC50 of 108.4 nM). However, 
when compared with primary fibroblasts, only AEE788 showed results similar to 
afatinib (non-tumor versus tumor ratio of 81 times). CO1686 (IC50 of 629.3 nM) and 
ceritinib (IC50 of 1,246 nM) showed modest differences between malignant and healthy 
cells (ratios of 2.4 and 1.3 times, respectively; see Figure S1B to S1F). We performed 
the survival assays at 7 days to better show longterm non-toxicity in primary fibroblasts; 
3 day treatments of gefitinib and afatinib also gave similar results (data not shown). We 
also confirmed gefitinib and afatinib inhibited non-FA HNSCCs in a similar trend (Figure 
S1H and data not shown). Thus, gefitinib and afatinib were the best anticancer drugs 
that specifically inhibited the growth of FA HNSCC cell lines at low-nanomolar 
concentrations. 
Gefitinib and afatinib are non-genotoxic in FANCA-deficient cells 
EGFR (ERBB-1) is a member of the ERBB family of tyrosine kinase receptors that has 
a central role in the tumorigenesis of many types of solid tumors, including HNSCC 
(31). Multiple drugs targeting these receptors have been approved for the treatment of 
several cancers, such as gefitinib and afatinib, as well as vandetanib and AZD9291 
(26–29). These drugs bind to the tyrosine kinase domain and impair kinase activity and 
downstream signaling pathways, such as PI3K/AKT and the RAS/MAPK axis. 
Moreover, no genotoxic toxicity is reported from these drugs. To discard any direct or 
indirect effect on DNA that could be easily repaired by normal cells but compromise FA 
cell viability, we treated U2OS cells with gefitinib or afatinib to analyze FANCD2 
monoubiquitination, a central step in the FA/BRCA pathway, induced by several types 
of DNA damage (2). As seen in Figure 2A and 2B, neither gefitinib nor afatinib up to 10 
M were able to activate the FA/BRCA pathway as measured by FANCD2 mono-
ubiquitination by Western blot, indicating that these drugs do not induce interstrand-
crosslinks (ICLs), stalled replication forks or double strand breaks on DNA that would 
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require processing by the FA pathway. We further analyzed their genotoxic capacity in 
FA cells, which are highly sensitive to ICLs such as diepoxybutane (32). Again, as seen 
in Figure 2C to 2G, high concentrations of gefitinib or afatinib were unable to induce 
chromosome fragility (micronuclei, MN) or G2/M cell cycle arrest (a specific hallmark of 
FA cells treated with ICL-inducing agents) in WT or FA lymphoblastoid cell lines, which 
express EGFR (Figure 2D) and are derived from T-cells reported to have a functional 
EGFR pathway (33,34).. In summary, our in vitro results showed that non-tumor FA 
cells could be safely treated with gefitinib and afatinib at therapeutic concentrations, as 
they did not activate the FA/BRCA pathway, nor induce chromosome fragility or cell 
cycle arrest in the absence of the FA pathway. 
EGFR pathway in FA HNSCCs 
Previous reports indicate that the EGFR pathway is functional in sporadic HNSCCs, 
and targeting this pathway inhibits tumor growth (35). Thus, we sought to further 
explore the EGFR pathway inhibition achieved by gefitinib and afatinib in FA HNSCCs. 
As shown in Figure 3A, 24 hours treatment with gefitinib or afatinib inhibited 
downstream signaling mediators of the EGFR pathway in all three FA HNSCC cell lines 
tested, such as phosphorylated AKT or ERK1/2. As previously reported in sporadic 
HNSCCs (36), we also observed that the EGFR pathway was overactivated in FA 
HNSCCs in comparison with primary fibroblasts, as detected by total and 
phosphorylated EGFR expression (Figure 3B). In the general population the majority of 
HNSCCs have mutations in TP53 (72 %) or PIK3CA (18 %) genes, but few in EGFR (4 
%) (35,37,38). Interestingly, van Zeeburg et al showed a similar TP53 mutation trend in 
FA HNSCCs (8 out of 13 FA HNSCCs tested, 62%, carried TP53 mutations) (39). 
Mutation analysis of key tumor-promoting genes showed that all three FA HNSCCs 
presented mutations in TP53, with a variant frequency of almost 100 % in DNA from 
the 1131 and 1604 cell lines, and 34 % from the 1365 cell line (Figure 3C and (24)). No 
other genes, such as EGFR, PIK3CA, AKT1, NRAS, or KRAS were found mutated in 
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these cell lines. Interestingly, EGFR MLPA assay showed a gain in EGFR copy number 
for 1131 and 1604 but not for 1365 cell lines (data not shown). These results highlight 
that FA HNSCC cell lines have a functional EGFR pathway similar to sporadic 
HNSCCs, with no mutations in key genes, increased EGFR activity and expression, in 
2 out of 3 cell lines with EGFR gene copy number gain, and functional AKT and 
ERK1/2 activities that could be inhibited by gefitinib and afatinib.  
 
Gefitinib and afatinib inhibit growth of FA HNSCCs in mouse xenografts 
To further investigate the therapeutic potential of gefitinib and afatinib for FA HNSCC, 
we used a preclinical mouse subcutaneous xenograft model. The FA HNSCC cell lines 
1604 and 1131 were subcutaneously implanted in NOD-SCID immunodeficient mice. 
Tumor growth was monitored over time, and when the tumors reached approximately 
150 mm3, animals were randomized into vehicle control groups or gefitinib (Figure 4) 
and afatinib (Figure 5) treatment groups. Importantly, treatment with these two 
FDA/EMA-approved EGFR inhibitors led to a significant reduction of the growth of the 
tumors compared to control animals at the end of the experiment (Figure 4A-C, E and 
Figure 5A-C, E), or a significant shrinkage of the size of the tumors compared to the 
size at the beginning of the treatment (Figure 4D, G, H and Figure 5D, G, H). 
Treatment did not have a major impact on mouse weight (Figure S2A-D). The efficacy 
of the treatment was further confirmed measuring the weight and the average volume 
change of the tumors at the end of the experiment (Figure S2E-L). Finally, tumors from 
vehicle-treated mice showed strong phospho-ERK immunostaining (Figure 4I-J, Figure 
5I-J and Figure S3), while tumors from gefitinib or afatinib-treated mice had almost no 
phospho-ERK signal, confirming a high efficiency of either drug in inhibiting the EGFR 
pathway in both HNSCC in vivo.  
Gefitinib and afatinib treatment did not produce hematotoxicity in Fanca-
deficient mice 
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Our in vitro results show gefitinib and afatinib are innocuous in FA fibroblast cells at 
therapeutic concentrations (Figure 2). The most frequently reported adverse effects 
(AEs) for these drugs in humans are skin rashes, diarrhea, and nausea and vomiting, 
among others (40–42). Thus, hematologic toxicity was not expected, but given the 
extreme fragility of FA patients, we sought to discard toxicity of these EGFR inhibitors 
in animal models of the disease. After two weeks of chronic administration of gefitinib 
or afatinib in wild type (WT) and Fanca-deficient mice, we monitored weight and 
general health status three times a week, hematological parameters before and at the 
end of the experiment, and bone marrow status when mice were sacrificed. As seen in 
Figure 6A, gefitinib treatment had no effects on body weight either in the WT or in 
Fanca-deficient mice. General health status showed no evident toxicity, specially skin 
rash or diarrhea, typical adverse effects reported for gefitinib and afatinib. We did not 
observe any differences in white or red blood cells, platelets, hemoglobin, hematocrit, 
or leukocyte populations from peripheral blood (CD4 and CD8 T-cells B-cells and 
myeloid cells), LSK+ cells or colony forming units (CFUs) from bone marrow (Figure 6, 
S4-S7). Following afatinib treatment, some Fanca-deficient mice showed weight loss 
during the first week of the treatment (Figure 7A). Clinical trials in HNSCC and NSCLC 
show that afatinib efficacy is higher than the standard of care but produces more 
toxicity and AEs than gefitinib. In these cases, a dose adjustment is often chosen with 
good results (43,44). For this reason, from day 7 we reduced afatinib dosages while 
maintaining its therapeutic effect (from 20 mg/kg/day to 15 mg/kg/day). Fanca-deficient 
mice progressed favorably after dose reduction and indeed recovered weight at the 
end of the experiment, also seen in wild type mice (Figure 7A and S4D). Afatinib 
administration also mildly reduced some hematological parameters, but in both WT and 
Fanca-deficient mice, and blood counts were always within the physiological range 
(Figure 7, S4, S6, and S7) (45). Notably, we did see an increase in blood myeloid cells 
in Fanca-deficient mice, which could suggest an increase in infection susceptibility, as 
previously reported for this drug (Figure S7B) (46,47). Finally, to exclude any in vivo 
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genotoxic effects on chromosomal stability, we analyzed MN presence in blood 
reticulocytes, which reflects acute chromosome fragility, and in erythrocytes, which 
represents chronic chromosomal instability in bone marrow erythroid precursors in vivo 
(17). Fanca-deficient mice spontaneously showed a reduction in reticulocyte counts 
(Figure S8A), while MN from erythrocytes or reticulocytes increased by more than two-
fold respect WT mice (Figure 6F and S8B). Interestingly, neither gefitinib nor afatinib 
treatment affected these chromosome fragility biomarkers in wild type or Fanca-
deficient mice, indicating that these EGFR inhibitors do not exert any clastogenic effect 
in the development of blood cells irrespective of the FA pathway. In summary, as seen 
in wild type and Fanca-deficient mice, gefitinib or afatinib administration is safe in vivo 
as a chronic treatment, with afatinib showing some toxicity that could be balanced by 
dose adjustment. 
DISCUSSION 
Twenty years ago, FA was mainly a pediatric disease, as most patients died in the first 
two decades due to bone marrow failure or leukemias (5). With improved 
transplantation protocols, FA patients now reach their fourth decade of life. Thus, 
HNSCC and other solid tumors are arising as the main challenge for their long-term 
survival, and last efforts in recent decades to treat patients with current therapies have 
resulted in poor survival rates. Due to its rare condition, few case reports have been 
published. Beginning in the 2000s, they highlighted the frequent clinical complications 
and severe toxicities of conventional chemotherapy and radiotherapy in these patients 
(8,9,48–50). On average, the median age reported at diagnosis has been 31-33 years, 
with a median follow-up of around 30-35 months, with very low tolerance to 
radiotherapy and chemotherapy. These case reports and small cohort studies highlight 
a painful reality and an unmet medical need that FA patients suffer nowadays: beyond 
tumor resection, there is no safe or effective treatment for FA patients with solid tumors 
in general, but especially HNSCCs. 
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Our work describes for the first time comprehensive preclinical data regarding gefitinib 
and afatinib, two previously approved anticancer drugs, with a strong potential for 
treating HNSCCs in FA. Drug validation in FA tumor and non-tumor cells identified 
several approved antitumor drugs inducing FA cancer-specific lethality, with gefitinib 
and afatinib having the best IC50 non-tumor/tumor ratio (Figure 1 and S1). Antibody-
based EGFR inhibitor cetuximab remains the only FDA-approved targeted therapy 
available for sporadic HNSCC, but it works in combination with radiotherapy or 
standard chemotherapy, which are not well-tolerated by FA patients (31). Indeed, 
Wong et al. and Kutler et al. have reported FA patients who received post-surgery 
cetuximab and radiotherapy. Two of them displayed lower toxicities and the other two 
had manageable toxicities, but all died of recurrent or metastatic disease (8,51). 
Unfortunately, without preclinical evidence of efficacy and safety and controlled studies 
such as with clinical trials, clinicians may find unsuitable to choose cetuximab as a 
single therapeutic option for FA patients. 
Our work shows that gefitinib and afatinib are effective in vitro in three different FA 
HNSCC cell lines (Figure 1) and more importantly in vivo, in xenograft experiments with 
immunodeficient mice with two different FA-patient derived HNSCC tumors (Figures 4, 
5, S2 and S3). In addition, our results also highlight that gefitinib and afatinib are safe 
in non-tumor FA cells, as they did not activate the FA/BRCA pathway nor induce 
chromosome instability (Figure 2), and more remarkably in Fanca-deficient mice; these 
drugs did not generate treatment-related hematotoxicity nor bone marrow failure 
(Figures 6, 7 and S4 to S8).  
Jung et al. published in 2005 a case report of a FA patient with a large squamous cell 
carcinoma on the tongue, which was 90% positive on EGFR according to 
immunohistochemical staining. The patient was then administered gefitinib as a 
palliative treatment, and after two months the tumor size was reduced by 80%, with no 
gefitinib-associated AEs such as skin rash or diarrhea (52). As shown here, our data 
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demonstrate both gefitinib and afatinib have cancer-specific lethality in FA HNSCC, 
with no toxicity targeting DNA, nor hematotoxicity in mouse models. We did observe 
some toxicity in afatinib-treated Fanca-deficient mice, which was reverted by dose 
adjustment, maintaining the therapeutic effect (Figure 7A and S4D). We did also 
observe an increase of myeloid cell populations (Figure S7), which suggests FA 
patients may need more thorough follow up with afatinib compared to gefitinib. 
Given that FA is a rare disease, the repositioning of approved medicines to achieve 
patient treatment is a viable approach regarding time and the cost/effectiveness ratio to 
market authorization (53,54). With this in mind, we recently received the orphan drug 
designation (ODD) status for gefitinib and afatinib by EMA to treat HNSCCs in FA 
patients (FDA orphan application submitted). ODD gives the sponsors regulatory 
benefits and facilities regarding reduced fees, scientific advice, protocol assistance, 
and market exclusivity after authorization, with the purpose to promote clinical trials 
that demonstrate safety and efficacy of new or repositioned drugs to treat rare 
diseases. This support from the European and American drug regulatory institutions 
may help to push current preclinical research to organize, coordinate, and initiate a 
multicenter, international clinical trial with gefitinib and/or afatinib to treat HNSCCs in 
FA with the aim to provide the patients a new anticancer therapeutic option and 
improve their clinical outcomes and quality of life. 
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Figure 1. Drug screening identified gefitinib and afatinib with antitumor activity in 
Fanconi anemia-derived HNSCCs, non-toxic for FA cells. A) FANCA-deficient 
U2OS cell line was used to screen for drugs with acute cytotoxicity. Non-genotoxic 
drugs with potential activity were selected and validated in FA HNSCCs and primary 
cells. B) Validation screening identified 7 potential drugs with high growth inhibition in 
three different FA HNSCCs while maintaining good viability in FA primary fibroblasts (at 
1 M). Bars show mean of samples performed at least in duplicates. C-E) Extended 
cytotoxicity analysis with gefitinib (D) and afatinib (E) in primary fibroblasts (from wild 
type, and FANCA-deficient patient) and three different FA HNSCC cell lines. Mitomycin 
C (C) was used as a control. The mean +/- SEM of at least three independent 
experiments is shown, with normalized curves in lines. F) IC50 (nM) of the candidate 
drugs used, in FA fibroblasts (green) and FA HNSCC cell lines (averaged, red). Ratio 
of non-tumor vs tumor IC50 (below) is shown to highlight best candidates (e.g. gefitinib, 
afatinib and AEE788). 
Figure 2. Best candidates gefitinib and afatinib are non-genotoxic. A-B) U2OS 
cells were stimulated for 24 hours with different concentrations of gefitinib (A), afatinib 
(B) or 2 mM HU (as a positive control). Cells were lysed and FANCD2 ubiquitination 
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analyzed by Western blot (upper panels) with vinculin used as a loading control. 
Averaged graphs of two independent experiments are shown in lower panels. C) 
Chromosomal fragility analysis by flow cytometry micronucleus assay (see materials 
and methods) using a FA lymphoblastoid cell line. Graphs show representative plots of 
MN (upper) and G2/M cell cycle (bottom). D-G) Graphs from experiments performed as 
in C, with WT (green bars) or FA-derived (red bars) lymphoblastoid cell lines. MN 
induction (D, F) and G2/M cell cycle arrest (E, G) of cells with different concentrations 
of gefitinib (D, E), and afatinib (F, G). Diepoxybutane (DEB) was used as a positive 
control. Bars show mean +/- SEM of three independent experiments with similar 
results. EGFR expression in lymphoblastoid cell lines is shown in a Western blot inside 
graph from figure 2D and is representative of two independent experiments. 
Figure 3. EGFR pathway in FA HNSCC cell lines. A) 1365 (left), 1131 (middle) and 
1604 (right) FA HNSCC cells were stimulated 24 hours with the indicated doses of 
gefitinib and afatinib, and Western blots for expression and phosphorylation status of 
key kinases of the EGFR pathway were performed. Vinculin was used as a loading 
control (p-Vinculin refers to membranes blotted with phospho-antibodies). Images are 
representative of at least three independent experiments with similar results. B) Total 
EGFR and phospho-EGFR basal expression in FA HNSCC in comparison with WT and 
FA primary fibroblasts (left panel). Relative expression normalized to WT primary 
fibroblasts is shown. Middle and right graph show mean +/- SEM of phospho-EGFR 
and total EGFR, respectively, of three independent experiments. C) Gene variants 
identified and their frequency in FA HNSCCs using TruSight Tumor 15 kit (see 
materials and methods).  
Figure 4. Gefitinib inhibits FA HNSCCs growth in vivo in mouse xenograft 
experiments. FA-derived HNSCC 1604 (A, C, D, G, I) and 1131 (B, E, F, H, J) 
xenografts are shown. A-B) Excised tumors at end-point. C, E) Tumor growth by 
vehicle (black lines) or gefitinib (blue lines) treatment groups. The arrow indicates the 
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start of the treatment. Graphs show mean +/- SEM. D, F) Response Evaluation Criteria 
In Solid Tumors (RECIST) classification from the percentage of tumor volume change. 
CR, complete response; PR, partial response; SD, stable disease; PD, progression 
disease G-H) Percentage of tumor volume change at baseline (start of treatment) for 
individual tumors (black bars, vehicle; blue bars, gefitinib). The percentage of tumor 
volume change of treated (T) vs vehicle (V) is shown. Dashed lines represent 20 % 
volume above and - 30 % below X axis. I-J) Immunohistochemistry of phospho-ERK 
activation in representative formalin fixed, paraffin-embedded tumors from xenografts 
treated with vehicle (upper) or gefitinib (lower). Student’s T-test: * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. 
Figure 5. Afatinib inhibits FA HNSCCs growth in vivo in mouse xenograft 
experiments. FA-derived HNSCC 1604 (A, C, D, G, I) and 1131 (B, E, F, H, J) 
xenografts are shown. A-B) Excised tumors at end-point. C, E) Tumor growth by 
vehicle (black lines) or afatinib (green lines) treatment. The arrow indicates the start of 
the treatment. Graphs show mean +/- SEM. D, F) RECIST classification from the 
percentage of tumor volume change, as shown in Figure 4D and 4F G-H) Percentage 
of tumor volume change at baseline (start of treatment) for individual tumors (black 
bars, vehicle; green bars, afatinib). The percentage of tumor volume change of treated 
(T) vs vehicle (V) is shown. Dashed lines represent 20 % volume above and - 30 % 
below the X axis. I-J) Immunohistochemistry of phospho-ERK activation in 
representative formalin-fixed paraffin-embedded tumors from xenografts treated with 
vehicle (upper) or afatinib (lower). Student’s T-test: * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001. 
Figure 6. Gefitinib is non-toxic in Fanca-deficient mice. A) Percentage body weight 
of wild type and Fanca-deficient mice, treated with vehicle or gefitinib (see materials 
and methods). B-C) Red blood cells (B) and platelets (C) at 0 and 14 days of vehicle or 
gefitinib treatment. Dashed blue lines in B show physiologic range of red blood cells. D-
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E) LSK+ cell percentage (D) and colony forming units (CFUs) capacity from bone 
marrow cells (E) at end-point (14 days). F-G) In vivo genotoxic analysis in murine blood 
cells. F) Percentage of erythrocytes with MN in wild type vs Fanca-deficient mice. G) 
Percentage of MN-erythrocytes in mice treated with vehicle or gefitinib. B to G graphs 
show data for individual mouse (green dots, wild type, red dots, Fanca-deficient) and 
mean +/- SEM. Student’s T-test: ns, not significant, * p<0.05, *** p<0.001. 
Figure 7. Afatinib is non-toxic in Fanca-deficient mice. A) Percentage body weight 
of wild type and Fanca-deficient mice, treated with vehicle or afatinib. From day 7, 
afatinib dose was reduced from 20 mg/kg/day to 15 mg/kg/day. B-C) Red blood cells 
(B) and platelets (C) at 0 and 14 days of vehicle or afatinib treatment. Dashed blue 
lines in B show physiologic range of red blood cells. D-E) LSK+ cell percentage (D) and 
colony forming units (CFUs) capacity from bone marrow cells (E) at end-point (14 
days). CFU graph shows afatinib data in blue dots superimposed to gefitinib data from 
Fig 6E. F) Percentage of MN-erythrocytes in mice treated with vehicle or afatinib. B to 
F graphs show data for individual mouse (green dots, wild type, red dots, Fanca-
deficient) and mean +/- SEM. T-test: ns, not significant, * p<0.05, ** p<0.01. 
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